Sugi Predict

Sugi Predict / Compounds / SCHEMBL1116004

SCHEMBL1116004

SCHEMBL1116004

COc1cc(Br)cc([N+](=O)[O-])c1N

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 5/20 0.49
▸ MEN1 O00255 3/20 0.49
▸ KMT2A Q03164 3/20 0.49
▸ KDM4E B2RXH2 2/20 0.49
▸ NPSR1 Q6W5P4 2/20 0.49
▸ MAPK1 P28482 2/20 0.49
▸ G6PD P11413 1/20 0.49
▸ PKM P14618 1/20 0.49
▸ RXFP1 Q9HBX9 1/20 0.49
▸ APOBEC3G Q9HC16 1/20 0.49
▸ HTT P42858 1/20 0.46
▸ ALDH1A1 P00352 5/20 0.46
▸ TDP1 Q9NUW8 3/20 0.46
▸ CYP3A4 P08684 2/20 0.45
▸ ALOX15 P16050 1/20 0.45
▸ PRKDC P78527 1/20 0.45
▸ HSD17B10 Q99714 1/20 0.45
▸ GAA P10253 1/20 0.41
▸ ABCB1 P08183 1/20 0.41
▸ ABCC1 P33527 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29549530 1.00 MAPT (0.49) MAPTMEN1KMT2AKDM4ENPSR1
SCHEMBL2088203 0.84 TUBB4A (0.49) MAPTMEN1KMT2AKDM4EMAPK1
SCHEMBL31423166 0.82 CYP1A2 (0.49) MAPTMEN1KMT2AKDM4ENPSR1
SCHEMBL1494444 0.82 CYP1A2 (0.49) MAPTMEN1KMT2AKDM4ENPSR1
SCHEMBL11273519 0.82 MAPT (0.66) MAPTMEN1KMT2AKDM4ENPSR1
SCHEMBL11524810 0.82 HTT (0.59) MAPTMEN1KMT2AKDM4ENPSR1
SCHEMBL13500386 0.82 MAPK1 (0.50) MAPTMEN1KMT2AKDM4ENPSR1
SCHEMBL29406556 0.82 HTT (0.59) MAPTMEN1KMT2AKDM4ENPSR1
SCHEMBL19764233 0.81 ALDH1A1 (0.43) MAPTMEN1KMT2AKDM4ENPSR1
SCHEMBL29505036 0.81 ALDH1A1 (0.44) MAPTMEN1KMT2AKDM4ENPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026087650-A1 VINYLOXY-ARYL COMPOUNDS FOR THE TREATMENT OF CANCER SANOFI (FR) 2026-04-30 — — WO disclosed
US-20250263408-A1 SPLEEN TYROSINE KINASE INHIBITORS UNIQUEST PTY LTD (AU) 2025-08-21 — — US disclosed
EP-4568946-A1 MACROCYCLIC BCL6 DEGRADERS Dana-Farber Cancer Institute, Inc. (US) 2025-06-18 — — EP disclosed
WO-2025085815-A1 PROTAC COMPOUNDS BINDING KEAP1 UBIQUITIN LIGASE FOR TARGETED PROTEIN DEGRADATION SEED THERAPEUTICS US, INC. (US) 2025-04-24 — — WO disclosed
WO-2025083472-A2 PROTAC COMPOUNDS BINDING KEAP1 UBIQUITIN LIGASE FOR TARGETED PROTEIN DEGRADATION SEED THERAPEUTICS US, INC. (US) 2025-04-24 — — WO disclosed
CN-119585240-A Macrocyclic BCL6 degrading agents 丹娜-法伯癌症研究院 2025-03-07 — — CN disclosed
EP-4504724-A1 SPLEEN TYROSINE KINASE INHIBITORS Uniquest Pty Limited (AU) 2025-02-12 — — EP disclosed
CN-119325474-A Spleen tyrosine kinase inhibitors 尤尼奎斯特公司 2025-01-17 — — CN disclosed
US-20240199613-A1 POLYCYCLIC INHIBITORS OF PLASMA KALLIKREIN TAKEDA PHARMACEUTICALS CO (JP) 2024-06-20 — — US disclosed
US-11957683-B2 Bicyclic compounds ALIGOS THERAPEUTICS, INC. (US) 2024-04-16 — — US disclosed
US-20120088767-A1 BENZIMIDAZOLE DERIVATIVES AS PI3 KINASE INHIBITORS GLAXOSMITHKLINE LLC 2012-04-12 — — US disclosed
US-8030497-B2 Benzimidazole derivatives NOVARTIS AG (CH) 2011-10-04 — — US disclosed
EP-2281819-A1 Benzimidazolyl or benzoxazolyl derivatives Novartis AG (CH) 2011-02-09 — — EP disclosed
US-20090298824-A1 Organic compounds PRESS NEIL J 2009-12-03 — — US disclosed
US-20090170921-A1 Benzimidazole derivatives NOVARTIS AG (CH) 2009-07-02 — — US disclosed
EP-1709006-A1 BENZIMIDAZOLE DERIVATIVES Novartis AG (CH) 2006-10-11 — — EP disclosed
EP-1709015-A1 ORGANIC COMPOUNDS Novartis AG (CH) 2006-10-11 — — EP disclosed
WO-2005068433-A9 BENZIMIDAZOLE DERIVATIVES NOVARTIS AG (CH) 2005-09-15 — — WO disclosed
WO-2005070906-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2005-08-04 — — WO disclosed
WO-2005068433-A1 BENZIMIDAZOLE DERIVATIVES NOVARTIS AG (CH) 2005-07-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170921-A1 Benzimidazole derivatives CYP3A7, UGT2B7, CYP2B6 MAPT 3722/4885MEN1 1810/4885KMT2A 3230/4885
US-20240199613-A1 POLYCYCLIC INHIBITORS OF PLASMA KALLIKREIN KLKB1, KLK1, KLK5 MAPT 3939/4885MEN1 379/4885KMT2A 851/4885
US-20120088767-A1 BENZIMIDAZOLE DERIVATIVES AS PI3 KINASE INHIBITORS PI4KB, PI4KA, PIK3CD MAPT 3376/4885MEN1 3694/4885KMT2A 2788/4885
US-11957683-B2 Bicyclic compounds SLC10A1, PKD1, CYP11B2 MAPT 1168/4885MEN1 262/4885KMT2A 3870/4885
US-20250263408-A1 SPLEEN TYROSINE KINASE INHIBITORS LCK, BTK, SYK MAPT 3900/4885MEN1 3587/4885KMT2A 1216/4885
US-20090298824-A1 Organic compounds CXCR2, CXCR3, CXCR1 MAPT 4012/4885MEN1 3708/4885KMT2A 3710/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.